SKOV‐3 ovarian tumor cells were chosen as the model to study the effect of tumor antigen obtained through HOCL‐oxidation; it induced rapid primary necrosis, enhanced the uptake of ovarian tumor by DCs, and primed autologous tumor‐specific CD4+ and CD8+ T cell responses.[194] In a pilot study of five patients with recurrent ovarian cancer, the immunogenicity, clinical efficacy, and progression‐free survival (PFS) of autologous DCs pulsed with HOCl‐oxidized autologous tumor lysate (OCDC vaccine) were evaluated. This evidence concerns the gene CD4 and ovarian neoplasm.